Less than a year after the global emergence of the coronavirus SARS-CoV-2, a novel
vaccine platform based on mRNA technology was introduced to the market. Globally, around …

Vaccinations against SARS-CoV-2 reduce the risk of developing serious COVID-19 disease.
Monitoring spike-specific IgG subclass levels after vaccinations may provide additional …

RNA vaccines are efficient preventive measures to combat the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) pandemic. High levels of neutralizing SARS-CoV-2 …

SARS-CoV-2 spike antigen-specific IgG and IgA elicited by infection mediate viral
neutralization and are likely an important component of natural immunity, however, limited …

Repeated doses of mRNA vaccines for COVID-19 result in increased proportions of anti-
spike antibodies of the IgG4 subclass, which are known to neutralize well and to form mixed …

Background Currently, evaluation of the IgG antibodies specific for the SARS-CoV-2 Spike
protein following vaccination is used worldwide to estimate vaccine response. Limited data …

Background The new types of mRNA-containing lipid nanoparticle vaccines BNT162b2 and
mRNA-1273 and the adenovirus-based vaccine AZD1222 were developed against SARS …

Research on coronavirus disease 2019 vaccination in immune-deficient/disordered people
(IDP) has focused on cancer and organ transplantation populations. In a prospective cohort …

The characterization of the adaptive immune response to COVID-19 vaccination in
individuals who recovered from SARS-CoV-2 infection may define current and future clinical …

Studies examining antibody responses by vaccine brand are lacking and may be informative
for optimizing vaccine selection, dosage, and regimens. The purpose of this study is to …